E

Everest Medicines Ltd
HKEX:1952

Watchlist Manager
Everest Medicines Ltd
HKEX:1952
Watchlist
Price: 44.92 HKD -2.14% Market Closed
Market Cap: 15.9B HKD
Section:
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
Everest Medicines Ltd

Wall Street analysts forecast Everest Medicines Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Everest Medicines Ltd is 73.32 HKD with a low forecast of 55.55 HKD and a high forecast of 92.4 HKD.

Lowest Forecast
Wall Street Target
55.55 HKD
24% Upside
Average Forecast
Wall Street Target
73.32 HKD
63% Upside
Highest Forecast
Wall Street Target
92.4 HKD
106% Upside
Lowest
Price Target
55.55 HKD
24% Upside
Average
Price Target
73.32 HKD
63% Upside
Highest
Price Target
92.4 HKD
106% Upside
Everest Medicines Ltd Competitors:
Price Targets
4
4BB
4Basebio PLC
139% Upside
KALV
Kalvista Pharmaceuticals Inc
194% Upside
GNS
Genus PLC
23% Upside
688235
Beigene Ltd
23% Upside
4
4BB
4Basebio PLC
139% Upside
KALV
Kalvista Pharmaceuticals Inc
194% Upside
GNS
Genus PLC
23% Upside
688235
Beigene Ltd
23% Upside
4593
Healios KK
55% Upside
ACAD
ACADIA Pharmaceuticals Inc
33% Upside
NRIX
Nurix Therapeutics Inc
134% Upside

Revenue
Forecast

Revenue Estimate
Everest Medicines Ltd

The compound annual growth rate of Everest Medicines Ltd's revenue for the next 3 years is 80%.

N/A
Past Growth
80%
Estimated Growth
Estimates Accuracy
-50%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Everest Medicines Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Everest Medicines Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Everest Medicines Ltd's stock price target?
Price Target
73.32 HKD

According to Wall Street analysts, the average 1-year price target for Everest Medicines Ltd is 73.32 HKD with a low forecast of 55.55 HKD and a high forecast of 92.4 HKD.

What is Everest Medicines Ltd's Revenue forecast?
Projected CAGR
80%

The compound annual growth rate of Everest Medicines Ltd's revenue for the next 3 years is 80%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 295,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.